Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.11.2009 | Epidemiology

Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists

verfasst von: Alice J. Sigurdson, Parveen Bhatti, Shih-chen Chang, Preetha Rajaraman, Michele M. Doody, Laura Bowen, Steven L. Simon, Robert M. Weinstock, Martha S. Linet, Marvin Rosenstein, Marilyn Stovall, Bruce H. Alexander, Dale L. Preston, Jeffery P. Struewing

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Ionizing radiation-associated breast cancer risk appears to be modified by timing of reproductive events such as age at radiation exposure, parity, age at first live birth, and age at menopause. However, potential breast cancer risk modification of low to moderate radiation dose by polymorphic estrogen metabolism-related gene variants has not been routinely investigated. We assessed breast cancer risk of 12 candidate variants in 12 genes involved in steroid metabolism, catabolism, binding, or receptor functions in a study of 859 cases and 1,083 controls within the US radiologic technologists (USRT) cohort. Using cumulative breast dose estimates from a detailed assessment of occupational and personal diagnostic ionizing radiation exposure, we investigated the joint effects of genotype on the risk of breast cancer. In multivariate analyses, we observed a significantly decreased risk of breast cancer associated with the CYP3A4 M445T minor allele (rs4986910, OR = 0.3; 95% CI 0.1–0.9). We found a borderline increased breast cancer risk with having both minor alleles of CYP1B1 V432L (rs1056836, CC vs. GG, OR = 1.2; 95% CI 0.9–1.6). Assuming a recessive model, the minor allele of CYP1B1 V432L significantly increased the dose–response relationship between personal diagnostic X-ray exposure and breast cancer risk, adjusted for cumulative occupational radiation dose (p interaction = 0.03) and had a similar joint effect for cumulative occupational radiation dose adjusted for personal diagnostic X-ray exposure (p interaction = 0.06). We found suggestive evidence that common variants in selected estrogen metabolizing genes may modify the association between ionizing radiation exposure and breast cancer risk.
Literatur
1.
Zurück zum Zitat Colditz GA et al (2006) Breast cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press Inc., NY, pp 995–1012 Colditz GA et al (2006) Breast cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press Inc., NY, pp 995–1012
2.
Zurück zum Zitat Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67–73PubMed Yager JD (2000) Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 27:67–73PubMed
5.
Zurück zum Zitat United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation: 2000 Report to the General Assembly, with scientific annexes. 2000, United Nations, New York United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation: 2000 Report to the General Assembly, with scientific annexes. 2000, United Nations, New York
10.
12.
Zurück zum Zitat Packer BR et al (2004) SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 32:D528–D532. doi:10.1093/nar/gkh005 Database issueCrossRefPubMed Packer BR et al (2004) SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 32:D528–D532. doi:10.​1093/​nar/​gkh005 Database issueCrossRefPubMed
14.
Zurück zum Zitat National Research Council Committee on the Biological Effects of Ionizing Radiations, BEIR VII: Health Risks from Exposure to Low Levels of Ionizing Radiation, National Academy Press, 1990: Washington D.C. National Research Council Committee on the Biological Effects of Ionizing Radiations, BEIR VII: Health Risks from Exposure to Low Levels of Ionizing Radiation, National Academy Press, 1990: Washington D.C.
15.
Zurück zum Zitat Land CE (1987) Temporal distributions of risk for radiation-induced cancers. J Chronic Dis 40(suppl 2):45S–57SCrossRefPubMed Land CE (1987) Temporal distributions of risk for radiation-induced cancers. J Chronic Dis 40(suppl 2):45S–57SCrossRefPubMed
17.
Zurück zum Zitat Rebbeck TR et al (2007) Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 166:1392–1399. doi:10.1093/aje/kwm239 CrossRefPubMed Rebbeck TR et al (2007) Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 166:1392–1399. doi:10.​1093/​aje/​kwm239 CrossRefPubMed
18.
19.
Zurück zum Zitat Ma H et al (2008) Low-dose medical radiation exposure and breast cancer risk in women under age 50 years overall and by estrogen and progesterone receptor status: results from a case–control and a case–case comparison. Breast Cancer Res Treat 109:77–90. doi:10.1007/s10549-007-9625-5 CrossRefPubMed Ma H et al (2008) Low-dose medical radiation exposure and breast cancer risk in women under age 50 years overall and by estrogen and progesterone receptor status: results from a case–control and a case–case comparison. Breast Cancer Res Treat 109:77–90. doi:10.​1007/​s10549-007-9625-5 CrossRefPubMed
21.
Zurück zum Zitat Milne RL et al (2008) The importance of replication in gene–gene interaction studies: miltifactor dimensionality reduction applied to a two-stage breast cancer case–control study. Carcinogenesis 29:1215–1218. doi:10.1093/carcin/bgn120 CrossRefPubMed Milne RL et al (2008) The importance of replication in gene–gene interaction studies: miltifactor dimensionality reduction applied to a two-stage breast cancer case–control study. Carcinogenesis 29:1215–1218. doi:10.​1093/​carcin/​bgn120 CrossRefPubMed
Metadaten
Titel
Polymorphisms in estrogen biosynthesis and metabolism-related genes, ionizing radiation exposure, and risk of breast cancer among US radiologic technologists
verfasst von
Alice J. Sigurdson
Parveen Bhatti
Shih-chen Chang
Preetha Rajaraman
Michele M. Doody
Laura Bowen
Steven L. Simon
Robert M. Weinstock
Martha S. Linet
Marvin Rosenstein
Marilyn Stovall
Bruce H. Alexander
Dale L. Preston
Jeffery P. Struewing
Publikationsdatum
01.11.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0307-3

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.